Ponesimod 20mg tablets
Requires a prescription from a doctor or prescriber
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Suspected adverse reactions reported for Ponesimod
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Ponesimod
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
MHRA licensed products
View all licensed products for Ponesimod on the MHRA register
Ponvory 20mg tablets
Therapeutically similar medicines
Similarity based on WHO Anatomical Therapeutic Chemical (ATC) classification and NHS BNF section grouping. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
Clinical guidelines and formulary information
British National Formulary
Ponesimod
Source: British National Formulary, NICE. Joint Formulary Committee. Contains public sector information licensed under the Open Government Licence v3.0.
NICE clinical guidance(4)
Ponesimod for treating relapsing–remitting multiple sclerosis (TA767)
Cladribine for treating active relapsing forms of multiple sclerosis (TA1053)
Natalizumab (originator and biosimilar) for treating highly active relapsing–remitting multiple sclerosis after disease-modifying therapy (TA1126)
Multiple sclerosis in adults: management (NG220)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & product information
Official product databases and supply status monitoring
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. emc (electronic medicines compendium) is operated by Datapharm Ltd. Shortage information sourced from NHS Specialist Pharmacy Service (SPS), sps.nhs.uk.
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF codes from NHS Business Services Authority (NHSBSA). ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Approved
Major interactions
None known
Half-life
33 hours
Mechanism
The sphingosine 1-phosphate receptor 1 (S1P1R) is expressed on the surface of ly…
Food interactions
1 warning
Human targets
1 target
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Absorption
10mg
[L32709]
Ponesimod reaches a Cmax of 109 ng/mL, with a Tmax of 4.0…
Half-life
33 hours
[L32709]
Protein binding
99%
[L32709]
Though the proteins it binds to have not been identified in literature.
[L32709]
Volume of distribution
160 L
[L32709]
Metabolism
Elimination
57.3-79.6%
[A232079][L32709]…
Clearance
3.8 L/h
[L32709]
Pharmacokinetic data: DrugBank · CC BY-NC 4.0
Ponesimod was granted FDA approval on 18 March 2021.[L32709]
[L32709]
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 1003 interactions
[L32709]
Patients should be monitored for pulse rate and blood pressure, as well as ECGs.
[L32709]
Treat patients with symptomatic and supportive measures, which may include [atropine] for bradycardia.
[L32709]
dialysis is not expected to remove a significant amount of drug from blood.
[L32709]
How the body processes this drug — absorption, distribution, metabolism, and elimination
[L32709]
Ponesimod reaches a Cmax of 109 ng/mL, with a Tmax of 4.0 hours, and an AUC of 3872 h\*ng/mL.
[A232079]
[L32709]
[L32709]
Though the proteins it binds to have not been identified in literature.
[L32709]
[L32709]
[A232079][L32709]
Ponesimod can also be oxidized by CYP2J2, CYP3A4, CYP3A5, CYP4F3A, and CYP4F12 to the M12 metabolite.
[A232079][L32709]
The undefined M27 metabolite can be glucuronidated by UGT1A1 and UGT 2B7 to the M38, M39, and M40 metabolites.
[A232079][L32709]
The M12 metabolite is either dealkylated to the M32 metabolite or oxidized and hydrolyzed to M13.
[A232079]
M13 is dealkylated to M32, which is reduced and oxidized to M48.
[A232079]
[A232079][L32709]
10.3-18.4% of an oral dose is eliminated in the urine.
[A232079][L32709]
0.6-1.9% of a radiolabelled dose was recovered as expired CO2.
[A232079]
[L32709]
Proteins and enzymes this drug interacts with in the body
Required for normal chemotaxis toward sphingosine 1-phosphate. Required for normal embryonic heart development and normal cardiac morphogenesis. Plays an important role in the regulation of sprouting angiogenesis and vascular maturation.
Inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development. Required for normal egress of mature T-cells from the thymus into the blood stream and into peripheral lymphoid organs. Plays a role in the migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis (By similarity).
Plays a role in responses to oxidized 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine by pulmonary endothelial cells and in the protection against ventilator-induced lung injury
Enzymes involved in drug metabolism — important for understanding drug interactions
ATC L04AE04
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Ponesimod
Additional database identifiers
Drugs Product Database (DPD)
23589
ChemSpider
9538103
BindingDB
50316768
ZINC
ZINC000034509627
HUGO Gene Nomenclature Committee (HGNC)
HGNC:3165
GeneCards
S1PR1
Guide to Pharmacology
275
UniProt Accession
S1PR1_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2634
GeneCards
CYP2J2
GenBank Gene Database
U37143
GenBank Protein Database
18254513
Guide to Pharmacology
1332
UniProt Accession
CP2J2_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2637
GenAtlas
CYP3A4
GeneCards
CYP3A4
GenBank Gene Database
M18907
Guide to Pharmacology
1337
UniProt Accession
CP3A4_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2638
GenAtlas
CYP3A5
GeneCards
CYP3A5
GenBank Gene Database
J04813
GenBank Protein Database
181346
Guide to Pharmacology
1338
UniProt Accession
CP3A5_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:2646
GeneCards
CYP4F3
UniProt Accession
CP4F3_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:18857
GeneCards
CYP4F12
Guide to Pharmacology
1348
UniProt Accession
CP4FC_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12530
GeneCards
UGT1A1
GenBank Gene Database
M57899
GenBank Protein Database
184473
Guide to Pharmacology
2990
UniProt Accession
UD11_HUMAN
HUGO Gene Nomenclature Committee (HGNC)
HGNC:12554
GeneCards
UGT2B7
GenBank Gene Database
J05428
GenBank Protein Database
340080
UniProt Accession
UD2B7_HUMAN
Patent information
4 active patents, 3 expired
Source: DrugBank · CC BY-NC 4.0. Patent data sourced from national patent offices. Expiry dates may not reflect extensions, regulatory exclusivity periods, or legal challenges.
DrugBank citations
If you use DrugBank data in your research, please cite the following publications: